The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY US Industry Opinion Divided on Japan’s Participation in TPP Talks
January 17, 2012
-
REGULATORY MHLW Proposes New Fee for Medical Management of Treatment-Resistant Schizophrenia
January 16, 2012
-
ORGANIZATION JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand
January 13, 2012
-
ORGANIZATION JPWA President Bessho Expresses Resolve for Distribution Improvement
January 12, 2012
-
BUSINESS Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
-
BUSINESS Bayer Yakuhin President Guth Says Marketing Success of 2 Strategic Products Key Focus
January 10, 2012
-
BUSINESS AZ to Utilize E-detailing, Optimize According to Product
January 6, 2012
-
ORGANIZATION FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
-
ORGANIZATION New Year’s Message: On behalf of the JPMA, I would like to express our best wishes for a Happy New Year as we see the start of 2012.
January 5, 2012
-
BUSINESS Aricept Overtakes Blopress to Take Top Spot in Domestic Drug Sales
December 28, 2011
-
REGULATORY Additional NHI Price Cuts Decided: ¥22.5 Billion for Long-Listed Drugs, ¥2.5 Billion for Generics
December 27, 2011
-
REGULATORY PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures
December 27, 2011
-
BUSINESS Chugai to Participate in Multinational Study of Avastin in Breast Cancer
December 27, 2011
-
REGULATORY Tougher Restrictions on Reimbursement of Vitamins to Cut ¥15 Bil. from Med. Expenditure
December 26, 2011
-
REGULATORY ¥25 Bil. to Be Saved through Add’l NHI Price Cuts for Both Long-listed, Generic Drugs in FY2012: MHLW
December 26, 2011
-
REGULATORY 0.9% Additional Price Cut for Long-Listed Drugs, Compensating Upward Revision of Nursing Fee: Minister Negotiation
December 22, 2011
-
BUSINESS Ranbaxy Settles with US FDA, Commits to Improvements in GMP Compliance, Data Integrity: Daiichi Sankyo
December 22, 2011
-
REGULATORY CSIMC Approves Additional Price Reduction for Long-listed Drugs Next Year
December 22, 2011
-
REGULATORY Price Cut Negotiations for Long-Listed Products Between MOF, Health Ministers “Parallel”
December 21, 2011
-
BUSINESS MTPC, Novartis Pharma Focused on Promoting Proper Use of MS Treatment Imusera/Gilenya
December 21, 2011
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…